8-K: Tango Therapeutics Advances TNG462 into Full Development Following Positive Clinical Trial Results, Announces New Brain-Penetrant Inhibitor

Tango Therapeutics is prioritizing its TNG462 program after promising clinical trial results and plans to advance a new brain-penetrant inhibitor, TNG456, into clinical trials.

Summary

• Tango Therapeutics reported its third quarter 2024 financial results and provided updates on its clinical programs.
• The company is advancing TNG462, a PRMT5 inhibitor, into full development based on positive phase 1/2 clinical trial data showing activity across multiple tumor types.
• TNG462 demonstrated a 43% overall response rate in cholangiocarcinoma patients (n=7).
• Tango is also developing TNG456, a next-generation brain-penetrant PRMT5 inhibitor, planned to enter clinical trials in the first half of 2025.
• The company has established a clinical collaboration with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) inhibitors.
• Tango's cash position is $293 million as of September 30, 2024, which is expected to fund operations into the third quarter of 2026.
• Collaboration revenue for the three months ended September 30, 2024, was $11.6 million, compared to $10.7 million for the same period in 2023.
• Research and development expenses were $33.3 million for the three months ended September 30, 2024, compared to $27.1 million for the same period in 2023.
• Net loss for the three months ended September 30, 2024, was $29.2 million, or $0.27 per share, compared to a net loss of $22.3 million, or $0.23 per share, in the same period in 2023.

Sentiment

Score: 8

Explanation: The document is positive due to the promising clinical data for TNG462, the strategic collaboration with Revolution Medicines, and the development of a new brain-penetrant inhibitor. The company's strong cash position and clear development plans also contribute to the positive sentiment. However, the increased net loss and R&D expenses temper the sentiment slightly.

Positives

• TNG462 has demonstrated promising clinical activity and durability across multiple tumor types.
• The collaboration with Revolution Medicines could lead to effective combination therapies.
• TNG456 has the potential to address brain tumors due to its brain-penetrant properties.
• The company has a strong cash position to support its clinical programs.
• The company is moving rapidly into the next phase of development for TNG462, including combination trials.

Negatives

• TNG908 did not demonstrate sufficient activity in glioblastoma due to inadequate central nervous system exposure.
• The company reported a net loss of $29.2 million for the third quarter of 2024, an increase from $22.3 million in the same period of 2023.
• Research and development expenses have increased to $33.3 million for the quarter, up from $27.1 million in the same period of 2023.

Risks

• Clinical trial results may not be consistent with preclinical data.
• The company has limited experience conducting clinical trials and relies on third parties.
• Tango may need to raise additional capital in the future.
• The company's approach to drug discovery is novel and unproven.
• There is a risk of delays in clinical trial initiation, enrollment, and reporting of results.

Future Outlook

Tango expects its current cash position to fund operations into the third quarter of 2026 and plans to initiate multiple combination trials for TNG462 and a phase 1/2 trial for TNG456 in the first half of 2025. The company also plans to share a clinical update on TNG462 in 2025.

Management Comments

• Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, stated that the combination of TNG462 with RAS(ON) inhibitors could be a powerful approach to changing the treatment landscape for pancreatic cancer.
• Adam Crystal, M.D., Ph.D., President, Research and Development of Tango Therapeutics, noted that patients remain on treatment with TNG462 with a current median of 24 weeks and is still increasing.
• Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, stated that the company is strongly positioned to achieve its goal of reaching as many patients as possible with MTAP-deleted cancers.

Industry Context

This announcement highlights the growing focus on precision medicine in cancer treatment, particularly the development of targeted therapies for specific genetic mutations. The collaboration with Revolution Medicines reflects a trend towards combining different targeted therapies to improve patient outcomes. The development of brain-penetrant drugs is also a key area of focus in oncology, as brain metastases are a significant challenge.

Comparison to Industry Standards

• The 43% ORR in cholangiocarcinoma with TNG462 is promising compared to standard chemotherapy options, which typically have lower response rates.
• The development of a brain-penetrant PRMT5 inhibitor like TNG456 addresses a critical unmet need in glioblastoma treatment, where many drugs fail to cross the blood-brain barrier.
• The collaboration with Revolution Medicines to combine TNG462 with RAS(ON) inhibitors is a novel approach, as RAS mutations are common in many cancers and difficult to target.
• Companies like Mirati Therapeutics and Amgen are also developing RAS inhibitors, but Tango's approach of combining a PRMT5 inhibitor with a RAS inhibitor is unique.
• The cash runway into 3Q 2026 is a positive sign for Tango, as many biotech companies struggle to secure funding for their clinical programs. This compares favorably to other companies in the same stage of development.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the clinical progress and strategic collaborations.
• Employees may be motivated by the company's advancements and growth.
• Patients with cancer may benefit from the development of new treatment options.
• The collaboration with Revolution Medicines could lead to new opportunities for both companies.

Next Steps

• Initiate multiple targeted and standard of care combination trials with TNG462 in 1H 2025.
• Begin enrollment in the phase 1/2 trial for TNG456 in 1H 2025.
• Provide a clinical data update for TNG462 in 2025.
• Continue the phase 1/2 clinical trial for TNG260.
• Initiate conversations with the FDA in preparation for multiple registrational studies.

Key Dates

Keywords

Tango Therapeutics, TNG462, TNG456, PRMT5 inhibitor, cancer, clinical trial, RAS(ON) inhibitor, glioblastoma, non-small cell lung cancer, pancreatic cancer, cholangiocarcinoma, biotechnology